Ascletis Pharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 1672.HK | ASND | ARWR | 688382.SS | AVIR | VIR | |
|---|---|---|---|---|---|---|
| Market cap | 5.13B | 16.97B | 8.71B | 8.38B | 357.71M | 1.99B |
| P/E (TTM) | — | 19.8 | — | — | — | — |
| Forward P/E | -17.5 | 25.8 | -12.4 | -43.8 | -3.0 | -4.8 |
| Price/book | 1.9 | 10.5 | 18.7 | 6.6 | 1.8 | 2.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −52.10% | +29.43% | +55.68% | −48.70% | +37.23% | +129.88% |
| Today | +7.23% | +3.10% | +3.56% | +4.33% | +6.95% | +4.90% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1672.HK news ›Ascletis Pharma Initiates Phase I Study In U S For Oral Amylin Receptor Peptide Agonist ASC36 For The Treatment Of Obesity
Ascletis Pharma Inc. has initiated a U.S. Phase I study of ASC36 oral tablets for the treatment of obesity after recently receiving Investigational New Drug clearance from the U.S. Food and Drug... has initiated a U.S Phase I study of…
Ascletis Pharma Inc. Submits FDA IND For ASC39 Oral Tablets For Treatment Of Obesity
Ascletis Pharma Inc. announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC39 oral tablets, an oral small molecule selective ... announced the submission of an…
Ascletis Pharma Begins Early-stage US Trial of Oral Tablets for Weight Loss
Ascletis Pharma commenced a phase 1 study for the ASC36 oral tablets in the U.S. for the treatment of obesity. The trial will study the safety, tolerability, pharmacokinetics, and pharmacodynamics... Ascletis Pharma Begins Early-stage US…
Hepatitis B Virus (HBV) Infection Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, GSK
Albany New York October 20 2026 As per DelveInsight s assessment globally Hepatitis B Virus HBV Infection pipeline constitutes 80 key companies continuously working towards developing 90 Hepatitis B Virus HBV Infection treatment therapies…
Ascletis Pharma Joins Two Chinese Stock Connect Programs
Ascletis Pharma said it has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Sept. 7. The inclusion allows mainland Chinese investors... Ascletis Pharma Joins Two Chinese Stock…
Ascletis Pharma Presents Preclinical Data for Weight Loss Drug at European Conference
Ascletis Pharma said it presented key preclinical data for its ASC36_35FDC in a short oral discussion at the 62nd European Association for the Study of Diabetes Annual Meeting in Milan,... Ascletis Pharma Presents Preclinical Data for…
Ascletis Pharma Inc.: Relative Strength Chart - Stock Hong Kong S.E.
Compare Ascletis Pharma Inc. with the company of your choice via a Relative Strength chart. Real-time 1672 price, Hong Kong S.E. stock exchange Relative Strength Chart Ascletis Pharma Inc. All financial news and data tailored to specific…
Ascletis Pharma Submits US IND Application for Oral Obesity Drug
Ascletis Pharma submitted an investigational new drug application to the U.S. FDA for ASC39, an oral small-molecule amylin receptor agonist for obesity, and expects to begin a Phase 1 trial in the... Ascletis Pharma Submits US IND…
Ascletis Pharma Inc. Announces Positive Preclinical Data For Once-Weekly Oral Peptide Pipeline For Treatment Of Obesity
Ascletis Pharma Inc. announced positive preclinical data demonstrating the long half-lives and superior bioavailability of its once-weekly oral peptide pipeline. The foundation of Ascletis?... announced positive preclinical data…
Ascletis Pharma Inc. Presents Key Preclinical Data For ASC36_35FDC At EASD 2026
Ascletis Pharma Inc. announced the presentation of key preclinical data for its ASC36_35FDC at the 62ndEuropean Association for the Study of Diabetes Annual Meeting, being held September 28?October... announced the presentation of key…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- marketscreener.com6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.